Although animal models are beneficial to research, they also have limitations. In part, this is due to the difference in biology between human and animal models. Microphysiology systems (MPS) are an emerging technology that holds the potential to increase translation and serve as a replacement or reduction for some animal models. Furthermore, these systems could improve efficiency, efficacy, and safety. MPS includes tissue models such as spheroids, organoids, and organs-on-chips.
Are you interested in learning more about microphysiological systems or using MPS in your current research?
Below is a list of current technology providers, organ systems, and contacts.
Are you working on microphysiological systems and don’t see your institution listed below?
Email us at email@example.com to join our MPS Hub and get your organization listed.
Organ Models: Brain, Spinal Nerve, Peripheral Nerve
Contact: Benjamin Cappiello
AxoSim develops biomimetic neuroscience discovery platforms, their Nerve-on-a-Chip and Mini-Brain technologies, to rapidly deliver clinically actionable human data with clinically- and in vivo-relevant metrics.
Organ Models: Gut, CNS, Kidney, Liver, Vascular, Solid Tumor
Contact: John Lowman
Mimetas builds higher-throughput organ-on-a-chip models in the OrganoPlate®, a 384-well plate modified with microfluidics to support structured, 3D tissue culture under continuous media perfusion.
Organ Models: Various single- and multi-organ models
TissUse develops single- and multi-organ-on-a-chip models based on its HUMIMIC technology platform. The systems incorporate major features of living biology such as pulsatile fluid flow, efficient nutrition, mechanical and electrical coupling, physiological tissue-to-fluid and tissue-to-tissue ratios.
Organ Models: Application areas include oncology, neuroscience, inflammation and toxicology with several validated models – Blood Brain Barrier, tumor, sepsis, vascular injury, inflammation and toxicology models like lung (air liquid interface), liver, gut, heart etc.
SynVivo’smicrofluidic tissue/organ-on-chip platform provides a biologically realistic microenvironment to enable better prediction of human relevant responses for drug development and personalized medicine applications. Complex in vivo microvascular environment including scale, morphology, hemodynamics and cellular architecture are re-created in vitro. SynVivo’s 3D cellular models feature a side-by-side architecture enabling real-time visualization and quantitation using standard analytical instrumentation.
Organ Models: liver, gut/gastrointestinal, vascular, kidney, tumor/immuno-oncology, blood-brain barrier
Contact: Joseph Charest
A microenvironment that can sustain human tissue organ models for several weeks of automated testing, Draper’s organ-on-chip platforms can array 96 independent single organ models in a high-throughput package (PREDICT96), link multiple organ models together (BIOMIMETICS), or culture patient-derived tissue samples (EVIDENT). Use Draper’s platforms to evaluate drug toxicity, measure efficacy in a disease state such as NASH (non-alcoholic steatohepatitis) and test immune-oncology therapies such as checkpoint inhibitors and combination therapies.
Organ Models: liver, pancreas, intestine
Contact: Nicola Gutteridge
DefiniGEN use iPSC differentiation technology to generate mature, phenotypically relevant human hepatocytes, pancreatic cells and intestinal organoids. Through sourcing patient samples and reprogramming to iPS or alternatively using CRISPR on the progenitor cell then differentiating, we can generate a range of unique metabolic disease models to support preclinical research.
Organ Models Services: healthy and diseased cardiac models, heart-on-a-chip
Contact: Krista Durney
TARA Biosystems generates human relevant cardiac data to enable faster, safer, and more accurate development of new medicines. TARA’s platform can reduce the cost and increase the success of important new medicines reaching patients.
Organ Models Services: Kidney, liver, liver-kidney combination, vasculature, blood-brain-barrier, cancer
Contact: Thomas Neumann
Nortis provides OOC-based solutions for toxicity screening and disease modeling. Researchers and drug developers can purchase Nortis’ ParVivo® technology for in-house studies or can opt to outsource studies to Nortis.